A Randomized, Double-blind, Active-controlled Clinical Trial, as Well as an Immuno-bridging Clinical Trial by Parallel Testing Previous Serum After Primary Immunization, to Evaluate the Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Coronavirus vaccine-Wuhan Institute of Biological Products (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sinovac Biotech
- 30 May 2024 Status changed from recruiting to completed.
- 11 Jan 2023 Planned primary completion date changed from 20 Nov 2022 to 20 Apr 2023.
- 15 Jun 2022 Status changed from not yet recruiting to recruiting.